ClinicalTrials.gg
RecruitingNCT05457049Updated Sep 16, 2026

Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD

An observational study in Non Small Cell Lung Cancer, sponsored by Guangdong Association of Clinical Trials. Recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Guangdong Association of Clinical Trials · Observational

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Association of Clinical Trials — 10 open to participants now, 13 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Guangdong Association of Clinical Trials.

Planned enrollment
8th of 10
180 · median 358
Started
2022
with 1 other
Observational
10 of 32
3 open now
Primary completion
2026-12
later than 5 of 12 live
Registered
22nd of 32
by date

Among the 32 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Association of Clinical Trials, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2022, is one of 10 observational ones, reaches primary completion later than 5 of the 12 other live ones, and was the 22nd registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

10 of the 32 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Association of Clinical Trials are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Carcinoma, Non-Small-Cell Lung by Guangdong Association of Clinical Trials, or all of them as a file.
02

Study summary

Molecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors. Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior prognostic factor for resected NSCLC patients, and not requiring excessive adjuvant therapy. Stage IB-IIIA resected NSCLC patients with landmark and longitudinal undetectable MRD are enrolled and under close surveillance in this study.

Read the detailed description

Stage IB-IIIA resected NSCLC patients will undergo two-round MRD tests after operation, first in 3-7 days and second in 1 month after operation. Patients who confirm two-round landmark undetectable MRD will be enrolled to be under close MRD and imaging monitoring without any adjuvant therapy. Patients who are MRD positive during the two-round MRD screening period will receive treatment and follow-up in accordance with Clinical Practice Guidelines.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • Molecular residual disease
  • Adjuvant therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Stage IB-IIIA NSCLC patients who after complete resection and undetectable landmark MRD.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage IB-IIIA non-small cell cancer patients who after complete resection.
  • ≥18 years.
  • Two-round MRD tests confirm landmark undetectable MRD.
  • Expected survival ≥12 weeks.
  • Expected survival ≥12 weeks.
  • PS 1-2.
  • Willing to accept MRD monitoring every 3 months for a total of 2 years after operation.

Exclusion criteria

Exclusion Criteria:

  • Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy.
  • Patients with a history of other in the past 5 years.
  • Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Undetectable MRD

    Stage IB-IIIA NSCLC patients who after complete resection. And patients who maintain MRD negativity in two-round MRD landmark test (first in 3-7 days after surgery, second in 1 months ±7 days after surgery) will be enrolled. And patients will be under close dynamic monitoring at least two years.

    Diagnostic Test: Molecular residual disease test

Interventions

  • Diagnostic testMolecular residual disease test

    OncoMRD Lung

06

What researchers measure

Primary outcomes

  1. Two-years disease free survival rates for patients with longitudinal undetectable MRD

    The 2-year DFS rate of patients who maintain 2-years undetectable MRD.

    Time frame: 2 year

Secondary outcomes

  1. Two-years disease free survival rates for patients with six months longitudinal undetectable MRD

    The 2-year DFS rate of patients who maintain 6-months undetectable MRD.

    Time frame: 2 year

  2. Two-years disease free survival rates for patients with 12-months longitudinal undetectable MRD

    The 2-year DFS rate of patients who maintain 12-months undetectable MRD.

    Time frame: 2 year

  3. Two-years disease free survival rates for patients with 18-months longitudinal undetectable MRD

    The 2-year DFS rate of patients who maintain 18-months undetectable MRD.

    Time frame: 2 year

  4. Two-years event-free survival rates for enrolled patients in two years

    The events are defined as disease recurrence or detectable MRD.

    Time frame: 2 year

  5. Two-years disease free survival rates for patients who tested positive for MRD and failed screening during the two-round MRD tests.

    The 2-year DFS rate of patients who tested positive for MRD and failed screening during the two-round MRD tests.

    Time frame: 2 year

07

Study locations

5 of 5 sites recruiting
  • The First People's Hospital of Foshan
    Foshan, Guangdong 528000, China
    Recruiting
  • Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences
    Guangzhou, Guangdong 510080, China
    Recruiting
    • Wen-Zhao Zhong, MD · Contact
    • Yi-Long Wu, MD · Contactsyylwu@live.cn · +86 20 83827812
    • Yi-Long Wu, MD · Principal investigator
    • Wen-Zhao Zhong, MD · Sub investigator
  • Shantou Centeral Hospital
    Shantou, Guangdong 515031, China
    Recruiting
  • the First Affiliated Hospital of Shantou University Medical College
    Shantou, Guangdong 515041, China
    Recruiting
  • Zhongshan City People's Hospital
    Zhongshan, Guangdong 528445, China
    Recruiting
08

References and documents

Publications

  • Zhang JT, Liu SY, Gao W, Liu SM, Yan HH, Ji L, Chen Y, Gong Y, Lu HL, Lin JT, Yin K, Jiang BY, Nie Q, Liao RQ, Dong S, Guan Y, Dai P, Zhang XC, Yang JJ, Tu HY, Xia X, Yi X, Zhou Q, Zhong WZ, Yang XN, Wu YL. Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer. Cancer Discov. 2022 Jul 6;12(7):1690-1701. doi: 10.1158/2159-8290.CD-21-1486. PubMed 35543554 ↗
  • Huang Z, He J, Li Y, Xu Z, Peng H, Gao X, Zhou H, Guo J, Yang N. Non-invasive radiogenomic mapping of the SMARCAL1-driven ferroptotic niche is associated with longitudinal MRD-negative surveillance in early-stage NSCLC. Front Immunol. 2026 May 25;17:1835413. doi: 10.3389/fimmu.2026.1835413. eCollection 2026. PubMed 42266691 ↗
  • Zhang JT, Dong S, Gu WQ, Zhao N, Liang Y, Tang WF, Liu SY, Wang F, Wang GS, Peng B, Wu N, Yan S, Geng GJ, Xie ZF, Yang YL, Zhang JH, Zhang T, Yang N, Jiao WJ, Xiong YY, Cai M, Li F, Chen RR, Yan HH, Maggie Liu SY, Yi X, Zhong WZ, Yang XN, Wu YL. Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201). Clin Lung Cancer. 2024 Jan;25(1):e1-e4. doi: 10.1016/j.cllc.2023.09.008. Epub 2023 Oct 6. PubMed 37880076 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.

Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 52 months is below that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2022
First posted
Jul 13, 2022
StartActual
Aug 1, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05457049
Lead sponsor
Guangdong Association of Clinical Trials
Responsible party
Yi-Long Wu (Principal Investigator, Guangdong Association of Clinical Trials) — Principal investigator
First posted
Jul 13, 2022
Start date
Aug 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 16, 2026

Study contacts

Yi-Long Wu, M.D
Contact
syylwu@live.cn
020-83827812
Xue-Ning Yang, Ph.D
Contact
yangxuening@gdph.org.cn
020-83827812

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion